Randomized trial of two different conditioning regimens for bone marrow transplantation in thalassemia - The role of busulfan pharmacokinetics in determining outcome

M. Chandy, P. Balasubramanian, S. V. Ramachandran, V. Mathews, B. George, D. Dennison, R. Krishnamoorthy, A. Srivastava

Research output: Contribution to journalArticle

39 Citations (Scopus)

Abstract

In total, 94 patients with homozygous beta thalassemia were randomized to two different conditioning regimens: busulfan 600mg/m2 +cyclophosphamide 200mg/kg or busulfan 16mg/kg+cyclophosphamide 200mg/kg and antilymphocyte globulin (47 in each group), for bone marrow transplantation, to see whether increased myeloablation or increased immunosuppression would reduce rejection. Busulfan pharmacokinetics in determining outcome was evaluated. There was no significant difference in engraftment, graft-versus-host disease, rejection, and overall and disease-free survival in the two groups. Systemic exposure to busulfan was significantly higher in the 600mg/m2 group, but in both groups there was a wide interindividual variation in the busulfan kinetics. Six patients rejected the graft, two in the busulfan 600mg group and four in busulfan 16mg group (P = 0.677 CI -0.17, 0.07), but in five patients (pharmacokinetic data not available in one patient) who rejected the graft busulfan first dose trough level (Cmin-1) was below 150ng/ml while it was above this level in the 66 of 68 patients with successful engraftment (P≤0.001). This randomized trial shows that rejection is influenced by busulfan levels and suggests that monitoring of busulfan levels and dose adjustment based on first-dose kinetics may reduce the risk of rejection.

Original languageEnglish
Pages (from-to)839-845
Number of pages7
JournalBone Marrow Transplantation
Volume36
Issue number10
DOIs
Publication statusPublished - Nov 2005

Fingerprint

Busulfan
Thalassemia
Bone Marrow Transplantation
Pharmacokinetics
Cyclophosphamide
Transplants
Antilymphocyte Serum
beta-Thalassemia
Graft vs Host Disease
Immunosuppression
Disease-Free Survival

Keywords

  • Busulfan
  • Pharmacokinetics
  • Thalassemia

ASJC Scopus subject areas

  • Hematology
  • Transplantation

Cite this

Randomized trial of two different conditioning regimens for bone marrow transplantation in thalassemia - The role of busulfan pharmacokinetics in determining outcome. / Chandy, M.; Balasubramanian, P.; Ramachandran, S. V.; Mathews, V.; George, B.; Dennison, D.; Krishnamoorthy, R.; Srivastava, A.

In: Bone Marrow Transplantation, Vol. 36, No. 10, 11.2005, p. 839-845.

Research output: Contribution to journalArticle

Chandy, M. ; Balasubramanian, P. ; Ramachandran, S. V. ; Mathews, V. ; George, B. ; Dennison, D. ; Krishnamoorthy, R. ; Srivastava, A. / Randomized trial of two different conditioning regimens for bone marrow transplantation in thalassemia - The role of busulfan pharmacokinetics in determining outcome. In: Bone Marrow Transplantation. 2005 ; Vol. 36, No. 10. pp. 839-845.
@article{16ec77a71cea4881ab22eb5e598dea61,
title = "Randomized trial of two different conditioning regimens for bone marrow transplantation in thalassemia - The role of busulfan pharmacokinetics in determining outcome",
abstract = "In total, 94 patients with homozygous beta thalassemia were randomized to two different conditioning regimens: busulfan 600mg/m2 +cyclophosphamide 200mg/kg or busulfan 16mg/kg+cyclophosphamide 200mg/kg and antilymphocyte globulin (47 in each group), for bone marrow transplantation, to see whether increased myeloablation or increased immunosuppression would reduce rejection. Busulfan pharmacokinetics in determining outcome was evaluated. There was no significant difference in engraftment, graft-versus-host disease, rejection, and overall and disease-free survival in the two groups. Systemic exposure to busulfan was significantly higher in the 600mg/m2 group, but in both groups there was a wide interindividual variation in the busulfan kinetics. Six patients rejected the graft, two in the busulfan 600mg group and four in busulfan 16mg group (P = 0.677 CI -0.17, 0.07), but in five patients (pharmacokinetic data not available in one patient) who rejected the graft busulfan first dose trough level (Cmin-1) was below 150ng/ml while it was above this level in the 66 of 68 patients with successful engraftment (P≤0.001). This randomized trial shows that rejection is influenced by busulfan levels and suggests that monitoring of busulfan levels and dose adjustment based on first-dose kinetics may reduce the risk of rejection.",
keywords = "Busulfan, Pharmacokinetics, Thalassemia",
author = "M. Chandy and P. Balasubramanian and Ramachandran, {S. V.} and V. Mathews and B. George and D. Dennison and R. Krishnamoorthy and A. Srivastava",
year = "2005",
month = "11",
doi = "10.1038/sj.bmt.1705151",
language = "English",
volume = "36",
pages = "839--845",
journal = "Bone Marrow Transplantation",
issn = "0268-3369",
publisher = "Nature Publishing Group",
number = "10",

}

TY - JOUR

T1 - Randomized trial of two different conditioning regimens for bone marrow transplantation in thalassemia - The role of busulfan pharmacokinetics in determining outcome

AU - Chandy, M.

AU - Balasubramanian, P.

AU - Ramachandran, S. V.

AU - Mathews, V.

AU - George, B.

AU - Dennison, D.

AU - Krishnamoorthy, R.

AU - Srivastava, A.

PY - 2005/11

Y1 - 2005/11

N2 - In total, 94 patients with homozygous beta thalassemia were randomized to two different conditioning regimens: busulfan 600mg/m2 +cyclophosphamide 200mg/kg or busulfan 16mg/kg+cyclophosphamide 200mg/kg and antilymphocyte globulin (47 in each group), for bone marrow transplantation, to see whether increased myeloablation or increased immunosuppression would reduce rejection. Busulfan pharmacokinetics in determining outcome was evaluated. There was no significant difference in engraftment, graft-versus-host disease, rejection, and overall and disease-free survival in the two groups. Systemic exposure to busulfan was significantly higher in the 600mg/m2 group, but in both groups there was a wide interindividual variation in the busulfan kinetics. Six patients rejected the graft, two in the busulfan 600mg group and four in busulfan 16mg group (P = 0.677 CI -0.17, 0.07), but in five patients (pharmacokinetic data not available in one patient) who rejected the graft busulfan first dose trough level (Cmin-1) was below 150ng/ml while it was above this level in the 66 of 68 patients with successful engraftment (P≤0.001). This randomized trial shows that rejection is influenced by busulfan levels and suggests that monitoring of busulfan levels and dose adjustment based on first-dose kinetics may reduce the risk of rejection.

AB - In total, 94 patients with homozygous beta thalassemia were randomized to two different conditioning regimens: busulfan 600mg/m2 +cyclophosphamide 200mg/kg or busulfan 16mg/kg+cyclophosphamide 200mg/kg and antilymphocyte globulin (47 in each group), for bone marrow transplantation, to see whether increased myeloablation or increased immunosuppression would reduce rejection. Busulfan pharmacokinetics in determining outcome was evaluated. There was no significant difference in engraftment, graft-versus-host disease, rejection, and overall and disease-free survival in the two groups. Systemic exposure to busulfan was significantly higher in the 600mg/m2 group, but in both groups there was a wide interindividual variation in the busulfan kinetics. Six patients rejected the graft, two in the busulfan 600mg group and four in busulfan 16mg group (P = 0.677 CI -0.17, 0.07), but in five patients (pharmacokinetic data not available in one patient) who rejected the graft busulfan first dose trough level (Cmin-1) was below 150ng/ml while it was above this level in the 66 of 68 patients with successful engraftment (P≤0.001). This randomized trial shows that rejection is influenced by busulfan levels and suggests that monitoring of busulfan levels and dose adjustment based on first-dose kinetics may reduce the risk of rejection.

KW - Busulfan

KW - Pharmacokinetics

KW - Thalassemia

UR - http://www.scopus.com/inward/record.url?scp=27844545839&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=27844545839&partnerID=8YFLogxK

U2 - 10.1038/sj.bmt.1705151

DO - 10.1038/sj.bmt.1705151

M3 - Article

C2 - 16151422

AN - SCOPUS:27844545839

VL - 36

SP - 839

EP - 845

JO - Bone Marrow Transplantation

JF - Bone Marrow Transplantation

SN - 0268-3369

IS - 10

ER -